Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis.
G KenetA OladapoJ D EpsteinChristin A ThompsonA NovackD J NugentPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2017)
A low dose ITI regimen with aPCC prophylaxis may be cost saving compared to a high dose ITI regimen with the potential to reduce morbidity by lowering the risk for breakthrough bleeds.